Search - tctmd.com

Displaying 1 - 20 of 328

Sort: Relevancy | Date

Beta-blockers Not Helpful After MI in Patients With Preserved EF

News Conference News AHA 2025

Beta-blockers Not Helpful After MI in Patients With Preserved EF

Yael L. Maxwell

November 12, 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

News Conference News AHA 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

November 08, 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

News Conference News ESC 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Michael O'Riordan

September 10, 2025

WHF Stresses the Importance of Polypills in Global Fight Against CVD

News Conference News ESC 2025

WHF Stresses the Importance of Polypills in Global Fight Against CVD

Yael L. Maxwell

September 09, 2025

DAPT’s Role After CABG Questioned: TACSI and TOP-CABG

News Conference News ESC 2025

DAPT’s Role After CABG Questioned: TACSI and TOP-CABG

September 05, 2025

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

News Conference News ESC 2025

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

Michael O'Riordan

September 04, 2025

HELP-MI SWEDEHEART: Routine H. Pylori Screening Doesn’t Lessen Bleeding After MI

News Conference News ESC 2025

HELP-MI SWEDEHEART: Routine H. Pylori Screening Doesn’t Lessen Bleeding After MI

September 03, 2025

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

News Conference News ESC 2025

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

September 01, 2025

No Benefit to Routine CT Angiography After Left Main PCI: PULSE

News Conference News ESC 2025

No Benefit to Routine CT Angiography After Left Main PCI: PULSE

Michael O'Riordan

August 31, 2025

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

News Conference News ESC 2025

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

Michael O'Riordan

August 30, 2025

Less Plaque With Intensive Medical Therapy vs Usual Care in INOCA: WARRIOR

News Conference News SCCT 2025

Less Plaque With Intensive Medical Therapy vs Usual Care in INOCA: WARRIOR

Yael L. Maxwell

July 28, 2025

AI-QCT Possibly Lessens Gap Between Ideal vs Actual Care for Patients at Risk of ASCVD

News Conference News SCCT 2025

AI-QCT Possibly Lessens Gap Between Ideal vs Actual Care for Patients at Risk of ASCVD

Yael L. Maxwell

July 22, 2025

AI-Based Coronary Plaque Analysis Can Inform Management Beyond CCTA: DECIDE Registry

News Conference News SCCT 2025

AI-Based Coronary Plaque Analysis Can Inform Management Beyond CCTA: DECIDE Registry

Yael L. Maxwell

July 21, 2025

‘Quick and Sustained’ Bumps in HR and BP When Beta-blockers Stopped Post-MI

News Conference News EuroPCR 2025

‘Quick and Sustained’ Bumps in HR and BP When Beta-blockers Stopped Post-MI

Michael O'Riordan

May 29, 2025

Short DAPT in High-Bleeding-Risk Patients Reduces Recurrent Events: MASTER DAPT

News Conference News EuroPCR 2025

Short DAPT in High-Bleeding-Risk Patients Reduces Recurrent Events: MASTER DAPT

Yael L. Maxwell

May 23, 2025

Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI

News Conference News EuroPCR 2025

Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI

Michael O'Riordan

May 20, 2025

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

News Conference News European Congress on Obesity 2025

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

Michael O'Riordan

May 14, 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

News Conference News ACC 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Michael O'Riordan

April 02, 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

News Conference News ACC 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

March 29, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.